These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31894801)

  • 1. Synthesis and antiproliferative activity of benzimidazole-based, trinuclear neutral cyclometallated and cationic, N
    Welsh A; Rylands LI; Arion VB; Prince S; Smith GS
    Dalton Trans; 2020 Jan; 49(4):1143-1156. PubMed ID: 31894801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, characterization and biological evaluation of cationic organoruthenium(ii) fluorene complexes: influence of the nature of the counteranion.
    Haghdoost MM; Golbaghi G; Guard J; Sielanczyk S; Patten SA; Castonguay A
    Dalton Trans; 2019 Sep; 48(35):13396-13405. PubMed ID: 31432885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
    Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
    J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarities and differences in d
    Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
    J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
    Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
    Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
    Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
    Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
    Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
    Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
    J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Characterization, and Cytotoxicity of Morpholine-Containing Ruthenium(II)
    Chatterjee R; Bhattacharya I; Roy S; Purkait K; Koley TS; Gupta A; Mukherjee A
    Inorg Chem; 2021 Aug; 60(16):12172-12185. PubMed ID: 34346215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
    Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
    Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
    Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
    J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
    Tabrizi L; Olasunkanmi LO; Fadare OA
    Dalton Trans; 2019 Jan; 48(2):728-740. PubMed ID: 30560261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, characterization and biological activity of new cyclometallated platinum(iv) iodido complexes.
    Bauer E; Domingo X; Balcells C; Polat IH; Crespo M; Quirante J; Badía J; Baldomà L; Font-Bardia M; Cascante M
    Dalton Trans; 2017 Nov; 46(43):14973-14987. PubMed ID: 29048088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Coordination Mode of Acylthiourea Ligands in Half-Sandwich Ru(II) Complexes and Their Cytotoxic Evaluation.
    Cunha BN; Luna-Dulcey L; Plutin AM; Silveira RG; Honorato J; Cairo RR; de Oliveira TD; Cominetti MR; Castellano EE; Batista AA
    Inorg Chem; 2020 Apr; 59(7):5072-5085. PubMed ID: 32208661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.